PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
Sisällön tarjoaa ReachMD. ReachMD tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!
Siirry offline-tilaan Player FM avulla!
Extending Treatment Durability With Next-Generation Neovascular AMD Therapies
MP3•Jakson koti
Manage episode 418198279 series 3128163
Sisällön tarjoaa ReachMD. ReachMD tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
CME credits: 0.50
Valid until: 25-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/extending-treatment-durability-with-next-generation-neovascular-amd-therapies/18067/
The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include recent data on the efficacy, safety, and durability of these new therapies and the imaging approaches that can be used to facilitate monitoring of nAMD disease progression and treatment success. This activity will create understanding of the new durable therapies and how they can extend dosing intervals. The expert faculty will discuss the latest data on new anti-VEGF therapies with the potential to reduce treatment burden and improve vision outcomes.
…
continue reading
Valid until: 25-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/extending-treatment-durability-with-next-generation-neovascular-amd-therapies/18067/
The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include recent data on the efficacy, safety, and durability of these new therapies and the imaging approaches that can be used to facilitate monitoring of nAMD disease progression and treatment success. This activity will create understanding of the new durable therapies and how they can extend dosing intervals. The expert faculty will discuss the latest data on new anti-VEGF therapies with the potential to reduce treatment burden and improve vision outcomes.
603 jaksoa
MP3•Jakson koti
Manage episode 418198279 series 3128163
Sisällön tarjoaa ReachMD. ReachMD tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
CME credits: 0.50
Valid until: 25-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/extending-treatment-durability-with-next-generation-neovascular-amd-therapies/18067/
The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include recent data on the efficacy, safety, and durability of these new therapies and the imaging approaches that can be used to facilitate monitoring of nAMD disease progression and treatment success. This activity will create understanding of the new durable therapies and how they can extend dosing intervals. The expert faculty will discuss the latest data on new anti-VEGF therapies with the potential to reduce treatment burden and improve vision outcomes.
…
continue reading
Valid until: 25-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/extending-treatment-durability-with-next-generation-neovascular-amd-therapies/18067/
The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include recent data on the efficacy, safety, and durability of these new therapies and the imaging approaches that can be used to facilitate monitoring of nAMD disease progression and treatment success. This activity will create understanding of the new durable therapies and how they can extend dosing intervals. The expert faculty will discuss the latest data on new anti-VEGF therapies with the potential to reduce treatment burden and improve vision outcomes.
603 jaksoa
Kaikki jaksot
×Tervetuloa Player FM:n!
Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.